Physician profile
Michael D Brown
NPI 1386614063
$2,205.03
in general payments reported to CMS, 2019-2025
30 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $132 · 2021: $75.65 · 2022: $233 · 2023: $360 · 2024: $361 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $245.40 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $217.34 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $209.93 | 2022-2025 | Jardiance, Mounjaro |
| Abbvie INC. | $203.90 | 2022-2025 | Qulipta |
| Exact Sciences Corporation | $135.63 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $131.11 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $104.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.07 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $87.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $66.17 | 2019-2025 | Gardasil 9, Vaqta, Vaxelis |
| Esperion Therapeutics, INC. | $62.71 | 2021 | |
| Harmony Biosciences LLC | $43.40 | 2025 | |
| Corcept Therapeutics | $39.12 | 2024-2025 | Korlym |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.00 | 2023-2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $36.02 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $34.95 | 2023-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $32.93 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $31.74 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $31.43 | 2019 | |
| Scpharmaceuticals INC. | $30.31 | 2025 | |
| Allergan, INC. | $24.94 | 2019 | |
| Eisai INC. | $21.91 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.01 | 2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $18.32 | 2019 | |
| Corium, LLC | $18.10 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $16.75 | 2023 | |
| Amgen INC. | $16.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.